Template:AHA non-statin cholesterol guidelines/2018
Jump to navigation
Jump to search
AHA/ACCP Cholesterol Clinical Practice Guidelines (2018, adapted)[1]
- Following patient-clinician discussion of benefit, safety, and cost, it is reasonable to add PCSK9 inhibitor in patients with clinical ASCVD at very high risk who are on maximally tolerated LDL-lowering therapy with LDL ≥70 mg/dL or non-HDL level of ≥100 mg/dL. (Class of recommendation: moderate benefit, level of evidence A)
- Based on 2018 data, PCSK9 inhibitors appear to be a low-value intervention (>$150,000 per QALY). (Level of evidence B, non-randomized)